Latest advances in AL amyloidosis treatment

During the 6th World Congress on Controversies in Multiple Myeloma (COMy) the Multiple Myeloma Hub spoke to Giampaolo Merlini, University of Pavia, Pavia,...

Is re-treatment possible with anti-CD38 therapies?

During the 6th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub spoke to Saad Usmani, Levine Cancer Institute,...

TOURMALINE-MM2 trial: Ixazomib with Rd versus Rd in newly diagnosed patients with MM

Transplant ineligible patients who are diagnosed with multiple myeloma (MM) are a diverse group; some are fit while...

Why do we need to harmonize the use of MRD in MM?

During the 6th World Congress on Controversies in Multiple Myeloma (COMy) the Multiple Myeloma Hub spoke to Bruno Paiva, University of Navarra,...

Should smoldering multiple myeloma be treated?

During the eighth annual meeting of the Society of Hematologic Oncology (SOHO), Angela Dispenzieri and Multiple Myeloma Hub Co-Chair, María-Victoria...

TOURMALINE-MM2 trial: Ixazomib with Rd versus Rd in newly diagnosed patients with MM

Transplant ineligible patients who are diagnosed with multiple myeloma (MM) are a diverse group; some are fit while...

Lymphodepletion optimization for CAR T-cell therapy

Chimeric antigen receptor (CAR) T-cell therapy is becoming more common in the treatment of both hematological and solid tumors. Prior to infusion,...

Why high-dose therapy plus auto-SCT still plays a role in newly diagnosed multiple myeloma

High-dose therapy (HDT), often coupled with autologous stem cell transplantation (auto-SCT), has been a...

Editorial theme | What you need to know about high-risk multiple myeloma

In this article, you will find reviews of the current clinical landscape of high-risk multiple myeloma that has already been...

How to achieve the best results in patients with high-risk MM

This month, the Multiple Myeloma Hub has been exploring the theme of high-risk multiple myeloma (MM). Treatment of patients with high-risk...

How to use MRD status to treat high-risk multiple myeloma

This month, the Multiple Myeloma Hub is exploring the theme of high-risk multiple myeloma (MM). The first article on this subject dealt with...

KRd plus auto-SCT induces high-quality durable responses in NDMM

The results of a phase II trial (NCT01816971) that investigated the addition of autologous stem cell transplantation (auto-SCT) to KRd...